Axis-shield Asa

Axis Biochemicals As

Axis Biochemicals Asa

Axis-shield As

Axis Research As

Abbott Rapid Diagnostics International Unlimited Company

Gentian As

Sundrehagen, Erling, Dr.

Axis-shield Diagnostics Limited

Sundrehagen, Erling

Erling Sundrehagen

Frank Frantzen

Lars Ørning

Arne Ludvig Faaren

Arne Kristian Nordhei

Lars Orning

David C Pritchard

Lars Örning

Tom Nilsen

Berit Løseth

Ken Milne

Asgeir Husa

Ingar Eilertsen

Jie Yang

Christian Melbø-Jørgensen

Torsten Knüttel

Ingvild Gudim

Ly Thi Tran

Julia Weikum

Arnaud David

The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component. The method includes: i) diluting the sample with a reagent mixture; ii) substantially removing blood cells; iii) using a reagent which serves to temporarily prevent reaction of the second component, to generate a blocked second component; iv) causing the selective reaction of a constituent of each analyte to directly or indirectly generate detectable reaction products, where one of the analytes is the first component; v) monitoring the detectable reaction product or products; vi) relating an amount of the detectable product or products and/or a rate of formation of the detectable product or products to the concentration of each analyte, where the concentration of at least the first component is related to a corresponding detectable reaction product by means of estimating an un-measurable (fictive) endpoint. Step iii) may be carried out at any stage up to and including step iv) but before steps v) or vi). The reagent of step iii) may be applied to the sample separately or may be included in a reagent mixture during steps i) or iv). A corresponding kit is also provided.

Blood sample assay method

NT-proBNP can be determined in a biological sample using at least one antibody which recognizes an epitope of NT-proBNP in both a glycosylated and non-glycosylated form of NT-proBNP. Said antibody is preferably an isolated polyclonal antibody or a mixture of monoclonal antibodies coated onto a particle, preferably coated onto said particle in a coating ratio of 6-60%, forming a layer or multiple layers of antibodies on said particle. The assay, realized in the form of a nephelometric or turbidimetric assay, can be applied to a wide range of automated clinical analyzers.

Highly sensitive particle enhanced assay for the quantification of NT-proBNP

An assay method for the detection of potential for CVD or propensity to CVD in a human or non-human animal subject, said method comprising assessing the concentration of calprotectin in a calprotectin-containing sample taken from said subject.

Determination method for calprotectin and the use of calprotectin as a predictive marker for cardiovascular disease

The present invention relates to assay methods for the determination of cobalamin or vitamin Bin a body fluid and in particular to assay methods for the metabolically active pool of cobalamin, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or holo TC II, separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.

Assay

The invention provides an assay method for the determination of transcobalamin II (TC II) bound cobalamin in a body sample, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or cobalamin bound TC II (holo TC II), separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.

Cobalamin assay

The invention relates to an assay method for assessing a transferrin variant or combination of transferrin variants for the diagnosis and monitoring of alcoholism, and to kits for performing the assay. In particular, the invention provides a method of producing an algorithm for determining the content of a transferrin variant or combination of transferrin variants, preferably a CDT variant or combination of CDT variants, in a sample of body fluid, said method comprising: (a) obtaining at least two solutions each having known contents of asialo- (A1, A2, A3, etc.) and disialo-transferrins (D1, D2, D3, etc.); (b) determining the content in each of said solutions of a transferrin variant or combination of transferrin variants fractions substantially free from tri- and higher sialylated transferring; (c) determining the total transferrin variant content (T1, T2, T2, etc.) of said fractions; and (d) producing an algorithm capable of determining the content of any transferrin variant or combination of transferrin variants, preferably a CDT variant or combination of CDT variants, in any given sample of body fluid subjected to said determination step b).

Transferrin assay

The invention relates to a new dipstick assay for detecting and quantifying the content of an target analyte in a sample. The assay is particularly useful for example in the diagnosis and monitoring of alcoholism by the detection of asialo transferrin or carbohydrate free transferrin (CFT). Thus, provided is a dipstick for determining the content of a target analyte variant in a mixture of analyte variants in a sample, comprising: a) a sample application zone, b) a screening zone having an immobilised binding ligand having a binding affinity for a non-target analyte variant or varinats, c) a conjugate zone comprising a detector reagent, d) a reading zone for detection of said analyte.

Dipstick for carbohydrate-free transferrin assay

An assay method for detecting potential cardiovascular disease (CVD) in a vascularized subject by assessing the concentration of holo-transcobalamin II (holo-TCII) in a sample from the subject where abnormally low levels of holo-TCII are indicative of CVD or susceptibility to CVD.

Assay method for cardiovascular disease

The invention provides a method of assessment of carbohydrate-deficient transferrin in a transferrin containing body fluid, said method comprising the steps of:

CDT assay

Immunoassay for homocysteine

The invention relates to a method for assaying homocysteine in a sample such as blood, plasma or urine, which comprises the steps of contacting the sample with a homocystene conveying enzyme and at least one substrate for the enzyme other than homocysteine, and without chromatographic separation, assessing a non-labelled analyte selected from a homotysteine co-substrate and the homocysteine conversion products of the enzymic conversion of homocysteine by said enzyme.

A method of assessing glycated blood protein in a sample which comprises separating glycated and non-glycated protein using a liquid phase precipitation reagent, contacting the sample with a signal forming agent capable of binding preferentially to the glycated protein, and assessing the signal forming agents.

Growing community of inventors

Oslo, Norway

Erling Sundrehagen